Research programme: GalNAc conjugated siRNA therapeutics - e-Therapeutics
Latest Information Update: 05 Dec 2023
At a glance
- Originator e-Therapeutics
- Class Amides; Amino sugars; Cardiovascular therapies; Drug conjugates; Hepatoprotectants; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 25 Oct 2023 GalNAc conjugated siRNA therapeutics are available for licensing as of 25 Oct 2023. https://www.etherapeutics.co.uk/partnering/ (e-Therapeutics website, October 2023)
- 25 Oct 2023 e-Therapeutics has patents pending for GalNAc conjugated siRNA therapeutics, before October 2023
- 25 Oct 2023 Preclinical trials in Cardiovascular disorders in United Kingdom (SC), before October 2023